AXGN Stock Overview
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
AxoGen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.77 |
52 Week High | US$10.83 |
52 Week Low | US$3.45 |
Beta | 1.07 |
1 Month Change | -25.65% |
3 Month Change | 12.94% |
1 Year Change | -14.71% |
3 Year Change | -61.65% |
5 Year Change | -62.81% |
Change since IPO | 186.72% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump
Mar 28Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost
Jan 26We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt
Sep 10Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues
Aug 09AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?
Jan 13Is AxoGen (NASDAQ:AXGN) A Risky Investment?
Sep 10AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings
Aug 02Axogen estimates Q2 revenue above consensus, reaffirms guidance
Jul 18Health Check: How Prudently Does AxoGen (NASDAQ:AXGN) Use Debt?
May 04Axogen Needs RECON More Than Ever To Recharge The Bull Case
Mar 08Is AxoGen (NASDAQ:AXGN) Using Debt Sensibly?
Dec 15Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing
Aug 25Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?
Aug 07Shareholder Returns
AXGN | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.4% | 2.2% | 0.4% |
1Y | -14.7% | 13.3% | 28.8% |
Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: AXGN underperformed the US Market which returned 29.5% over the past year.
Price Volatility
AXGN volatility | |
---|---|
AXGN Average Weekly Movement | 10.2% |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXGN's share price has been volatile over the past 3 months.
Volatility Over Time: AXGN's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 427 | Karen Zaderej | https://www.axogeninc.com |
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AxoGen, Inc. Fundamentals Summary
AXGN fundamental statistics | |
---|---|
Market cap | US$335.71m |
Earnings (TTM) | -US$21.72m |
Revenue (TTM) | US$159.01m |
2.1x
P/S Ratio-15.5x
P/E RatioIs AXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AXGN income statement (TTM) | |
---|---|
Revenue | US$159.01m |
Cost of Revenue | US$31.14m |
Gross Profit | US$127.87m |
Other Expenses | US$149.59m |
Earnings | -US$21.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.50 |
Gross Margin | 80.42% |
Net Profit Margin | -13.66% |
Debt/Equity Ratio | 51.8% |
How did AXGN perform over the long term?
See historical performance and comparison